Investment Thesis
electroCore share price performance since IPO. Source: TradingView.
electroCore (NASDAQ:ECOR) has been a crushing disappointment for its investors since its June 2018 IPO. Despite the promise of its FDA approved, non-invasive treatment for migraines - gammaCore - cleared for the acute and preventive treatment of migraines and episodic cluster headaches - there is now significant doubt as to whether it will be able to retain its listing on the Nasdaq given that the stock currently trades below $1, and a reasonable chance that electroCore will have to cease operations altogether.